key: cord-1051003-vflow3z4 authors: Basu, Soumya; Veeraraghavan, Balaji; Ramaiah, Sudha; Anbarasu, Anand title: Novel cyclohexanone compound as a potential ligand against SARS-CoV-2 main-protease date: 2020-10-01 journal: Microb Pathog DOI: 10.1016/j.micpath.2020.104546 sha: 50c52e597af8b9e54d4bc14f7773dbc46c6f2af2 doc_id: 1051003 cord_uid: vflow3z4 No commercially available drug candidate has yet been devised which is unique to and not repurposed against SARS-CoV-2 and has high efficacy or safe toxicity profile or both. Taking curcumin as a reference compound, we identified a new commercially available cyclohexanone compound, ZINC07333416 with binding energy (−8.72 kcal/mol) better than that of popularly devised anti-Covid-19 drugs like viral protease inhibitor Lopinavir, nucleoside analogue Remdesivir and the repurposed drug hydroxychloroquine when targeted to the active-site of SARS-CoV-2 Main protease (Mpro) through docking studies. The ligand ZINC07333416 exhibits crucial interactions with major active site residues of SARS-CoV-2 Mpro viz. Cys145 and His41 involving in the protease activity; as well as GLU-166 and ASN-142 which plays the pivotal role in the protein-dimerization. The protein-ligand stable interaction was further confirmed with molecular dynamics simulation (MDS) studies. Based on virtual assessment, ZINC07333416 also have significant values in terms of medicinal chemistry, pharmacokinetics, synthetic accessibility and anti-viral activity that encourage its experimental applications against COVID-19. No commercially available drug candidate has yet been devised which is unique to and not 26 repurposed against SARS-CoV-2 and has high efficacy or safe toxicity profile or both. Taking victims. [3] We also objectified on comparing the same with popular drugs devised against 58 COVID-19 [3] [4] [5] in terms of interaction, toxicity profiles and drug properties in-silico. 59 Curcumin was chosen in our study as a reference to screen analogous compounds since it has 60 anti-viral activity and a safe toxicity profile. [6, 7] The three-dimensional (3D) structure of SARS- Rapid Identification of Potential 254 Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus 262 (2019-nCoV) in vitro Ellagic acid synergistically induce ROS generation, DNA damage, p53 accumulation and 266 apoptosis in HeLa cervical carcinoma cells Multisite inhibitors for enteric 269 coronavirus: antiviral cationic carbon dots based on curcumin Open Babel: An Open chemical toolbox SwissSimilarity: A Web Tool for Low to 275 Ultra High Throughput Ligand-Based Virtual Screening AutoDock4 and AutoDockTools4: Automated docking with selective 280 receptor flexibility Evidence for Substrate Binding-Induced Zwitterion Formation in the Catalytic Cys-His Dyad of the 284 SARS-CoV Main Protease AVCpred: an integrated web server for prediction and 287 design of antiviral compounds SwissADME: A free web tool to evaluate 290 pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules Pharmacokinetic Properties and ADME Modeling in Drug Discovery Estimation of synthetic accessibility score of drug-like 296 molecules based on molecular complexity and fragment contributions ProTox-II: A webserver for the 299 prediction of toxicity of chemicals Structural insight into conformational We would also like to thank the anonymous Reviewer for his/her valuable suggestions and appreciate his/her time spent on reviewing our manuscript.We imply that 1. It has not been published previously. 2. It has not been submitted elsewhere. We would be pleased if you could send the manuscript to appropriate reviewers and oblige.With regards, Sincerely Yours, Tel: +91-416-2202547. Fax: +91-416-2243092.E-mail address: anand@vit.ac.in